Oil prices climbed again on Friday as armed clashes intensify in Israel and, increasingly, beyond.
In an interview, OpenAI’s CEO Sam Altman discusses job disruption, data and the ‘person-ness’ of bots.
Eli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound.
Back in 1994, bonds with fabulous yields were there for the taking. Our columnist doesn’t see treasures like that now, but there are solid buys.
Many of Uncle Sam’s bonds linked to inflation, called TIPS, performed horribly last year. It’s time to give them another look.
The Northeast is bracing for higher heating-oil bills than last year.
Endless manufacturing defects affecting newer planes increase the useful life of older models. Investors should take note.
The 10-year yield is close to hitting 5% for the first time since 2007. We asked some of Wall Street’s brightest how to play it.
Demand for GLP-1 weight loss drugs could be a net positive for insurance companies with pharmacy-benefit businesses.
The past year’s stock-market rally looks more like the tail end of a bull run, rather than the beginning.